Cost-effectiveness of hepatitis C virus (HCV) elimination strategies among people who inject drugs (PWID) in Tijuana, Mexico.
Cost-effectiveness
HCV
harm reduction
modeling
people who inject drugs
prevention
Journal
Addiction (Abingdon, England)
ISSN: 1360-0443
Titre abrégé: Addiction
Pays: England
ID NLM: 9304118
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
revised:
23
11
2020
received:
11
06
2020
accepted:
10
02
2021
pubmed:
24
2
2021
medline:
30
9
2021
entrez:
23
2
2021
Statut:
ppublish
Résumé
In Latin America, Mexico was first to launch a hepatitis C virus (HCV) elimination strategy, where people who inject drugs (PWID) are a main risk group for transmission. In Tijuana, HCV seroprevalence among PWID is > 90%, with minimal harm reduction (HR). We evaluated cost-effectiveness of strategies to achieve the incidence elimination target among PWID in Tijuana. Modeling study using a dynamic, cost-effectiveness model of HCV transmission and progression among active and former PWID in Tijuana, to assess the cost-effectiveness of incidence elimination strategies from a health-care provider perspective. The model incorporated PWID transitions between HR stages (no HR, only opioid agonist therapy, only high coverage needle-syringe programs, both). Four strategies that could achieve the incidence target (80% reduction by 2030) were compared with the status quo (no intervention). The strategies incorporated the number of direct-acting anti-viral (DAA) treatments required with: (1) no HR scale-up, (2) HR scale-up from 2019 to 20% coverage among PWID, (3) HR to 40% coverage and (4) HR to 50% coverage. Costs (2019 US$) and health outcomes [disability-adjusted life years (DALYs)] were discounted 3% per year. Mean incremental cost-effectiveness ratios (ICER, $/DALY averted) were compared with one-time per capita gross domestic product (GDP) ($9698 in 2019) and purchasing power parity-adjusted per capita GDP ($4842-13 557) willingness-to-pay (WTP) thresholds. DAAs alone were the least costly elimination strategy [$173 million, 95% confidence interval (CI) = 126-238 million], but accrued fewer health benefits compared with strategies with HR. DAAs + 50% HR coverage among PWID averted the most DALYs but cost $265 million, 95% CI = 210-335 million). The optimal strategy was DAAs + 50% HR (ICER $6743/DALY averted compared to DAAs only) under the one-time per-capita GDP WTP ($9698). A combination of high-coverage harm reduction and hepatitis C virus treatment is the optimal cost-effective strategy to achieve the HCV incidence elimination goal in Mexico.
Sections du résumé
BACKGROUND AND AIMS
In Latin America, Mexico was first to launch a hepatitis C virus (HCV) elimination strategy, where people who inject drugs (PWID) are a main risk group for transmission. In Tijuana, HCV seroprevalence among PWID is > 90%, with minimal harm reduction (HR). We evaluated cost-effectiveness of strategies to achieve the incidence elimination target among PWID in Tijuana.
METHODS
Modeling study using a dynamic, cost-effectiveness model of HCV transmission and progression among active and former PWID in Tijuana, to assess the cost-effectiveness of incidence elimination strategies from a health-care provider perspective. The model incorporated PWID transitions between HR stages (no HR, only opioid agonist therapy, only high coverage needle-syringe programs, both). Four strategies that could achieve the incidence target (80% reduction by 2030) were compared with the status quo (no intervention). The strategies incorporated the number of direct-acting anti-viral (DAA) treatments required with: (1) no HR scale-up, (2) HR scale-up from 2019 to 20% coverage among PWID, (3) HR to 40% coverage and (4) HR to 50% coverage. Costs (2019 US$) and health outcomes [disability-adjusted life years (DALYs)] were discounted 3% per year. Mean incremental cost-effectiveness ratios (ICER, $/DALY averted) were compared with one-time per capita gross domestic product (GDP) ($9698 in 2019) and purchasing power parity-adjusted per capita GDP ($4842-13 557) willingness-to-pay (WTP) thresholds.
RESULTS
DAAs alone were the least costly elimination strategy [$173 million, 95% confidence interval (CI) = 126-238 million], but accrued fewer health benefits compared with strategies with HR. DAAs + 50% HR coverage among PWID averted the most DALYs but cost $265 million, 95% CI = 210-335 million). The optimal strategy was DAAs + 50% HR (ICER $6743/DALY averted compared to DAAs only) under the one-time per-capita GDP WTP ($9698).
CONCLUSIONS
A combination of high-coverage harm reduction and hepatitis C virus treatment is the optimal cost-effective strategy to achieve the HCV incidence elimination goal in Mexico.
Identifiants
pubmed: 33620750
doi: 10.1111/add.15456
pmc: PMC8380744
mid: NIHMS1708013
doi:
Substances chimiques
Antiviral Agents
0
Pharmaceutical Preparations
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2734-2745Subventions
Organisme : NIAID NIH HHS
ID : R01 AI147490
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI036214
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA023356
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA049644
Pays : United States
Organisme : NIDA NIH HHS
ID : K01 DA043421
Pays : United States
Informations de copyright
© 2021 Society for the Study of Addiction.
Références
Drug Alcohol Depend. 2019 May 1;198:80-86
pubmed: 30884432
Int J Epidemiol. 2014 Feb;43(1):235-48
pubmed: 24374889
J Hepatol. 2006 Jan;44(1):158-66
pubmed: 16290309
Subst Abuse Treat Prev Policy. 2013 Oct 01;8:35
pubmed: 24079946
J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):369-76
pubmed: 18176320
Antiviral Res. 2015 Jul;119:89-96
pubmed: 25615583
Hepatology. 2013 Nov;58(5):1598-609
pubmed: 23553643
Lancet Glob Health. 2017 Dec;5(12):e1208-e1220
pubmed: 29074410
Lancet Gastroenterol Hepatol. 2018 Dec;3(12):819
pubmed: 30507463
Hepatology. 2008 Aug;48(2):418-31
pubmed: 18563841
Curr Opin HIV AIDS. 2015 Sep;10(5):374-80
pubmed: 26248124
BMJ Open. 2019 Jan 29;9(1):e026298
pubmed: 30700490
PLoS One. 2014 Jan 28;9(1):e86584
pubmed: 24489747
Int J Drug Policy. 2021 Feb;88:102710
pubmed: 32165050
Lancet Glob Health. 2015 Nov;3(11):e712-23
pubmed: 26475018
Addiction. 2019 Dec;114(12):2267-2278
pubmed: 31307116
Salud Publica Mex. 2007 May-Jun;49(3):165-72
pubmed: 17589770
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176
pubmed: 28404132
Clin Infect Dis. 2013 Aug;57 Suppl 2:S39-45
pubmed: 23884064
AIDS Behav. 2016 May;20(5):1017-25
pubmed: 26354518
Harm Reduct J. 2014 Jan 14;11:1
pubmed: 24422784
BMJ. 2010 Oct 26;341:c5475
pubmed: 20978062
Hepatology. 2002 Nov;36(5 Suppl 1):S114-20
pubmed: 12407584
AIDS Patient Care STDS. 2010 Dec;24(12):753-62
pubmed: 21138381
Int J Drug Policy. 2018 Jul;57:104-110
pubmed: 29715589
Int J Drug Policy. 2012 Jul;23(4):286-94
pubmed: 22676968
Lancet Public Health. 2018 Sep;3(9):e429-e437
pubmed: 30122559
Addiction. 2018 Mar;113(3):545-563
pubmed: 28891267
Ann Intern Med. 2016 Nov 1;165(9):625-634
pubmed: 27537841
AIDS Patient Care STDS. 2008 Jan;22(1):53-64
pubmed: 18095839
Lancet Gastroenterol Hepatol. 2018 Mar;3(3):153-161
pubmed: 29310928
Hepatology. 2012 Jan;55(1):49-57
pubmed: 21898506
J Psychoactive Drugs. 2005 Sep;37(3):333-9
pubmed: 16295018
Harm Reduct J. 2018 May 23;15(1):28
pubmed: 29792191
Psychol Health Med. 2019 Apr;24(4):439-445
pubmed: 30453760
Harm Reduct J. 2014 Feb 12;11:4
pubmed: 24520885
Hepatology. 2009 Apr;49(4):1335-74
pubmed: 19330875
Value Health. 2016 Dec;19(8):929-935
pubmed: 27987642
J Viral Hepat. 2006 Jan;13(1):34-41
pubmed: 16364080
BMJ. 2017 Apr 26;357:j1550
pubmed: 28446428
Addiction. 2012 Nov;107(11):1984-95
pubmed: 22564041
Glob Public Health. 2015;10(3):296-317
pubmed: 25469976
Liver Int. 2020 Oct;40(10):2356-2366
pubmed: 32475010
Harm Reduct J. 2016 Sep 15;13(1):25
pubmed: 27629248
Hepatology. 2013 Apr;57(4):1333-42
pubmed: 23172780
PLoS One. 2017 May 17;12(5):e0176503
pubmed: 28520728
Lancet Glob Health. 2017 Dec;5(12):e1192-e1207
pubmed: 29074409
J Urban Health. 2006 Nov;83(6 Suppl):i83-97
pubmed: 17072761
Arch Med Res. 2006 Jul;37(5):663-73
pubmed: 16740439
Int J Drug Policy. 2020 Jan;75:102601
pubmed: 31775080
J Subst Abuse Treat. 2010 Jul;39(1):22-31
pubmed: 20418051
Health Technol Assess. 2007 Mar;11(11):1-205, iii
pubmed: 17346498
Addict Behav. 2018 Jan;76:305-311
pubmed: 28889059